$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

$egrx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000082787123000016 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$64.65M	$66.31M
YoY Change	-12.8%	-42.78%
Cost Of Revenue	$16.86M	$17.30M
YoY Change	-28.76%	-31.28%
Gross Profit	$47.79M	$49.01M
YoY Change	-5.32%	-45.97%
Gross Profit Margin	73.92%	73.91%
Selling, General & Admin	$27.65M	$27.96M
YoY Change	-24.93%	26.05%
% of Gross Profit	57.86%	57.06%
Research & Development	$9.833M	$9.272M
YoY Change	-14.02%	51.8%
% of Gross Profit	20.58%	18.92%
Depreciation & Amortization	$100.0K	$100.0K
YoY Change	-93.88%	-50.0%
% of Gross Profit	0.21%	0.2%
Operating Expenses	$37.48M	$37.23M
YoY Change	-22.34%	31.61%
Operating Profit	$10.30M	$11.77M
YoY Change	367.73%	-80.32%
Interest Expense	$1.448M	$1.516M
YoY Change	-243.65%	314.21%
% of Operating Profit	14.05%	12.88%
Other Income/Expense, Net	-$1.006M	-$1.542M
YoY Change	-85.76%	-28.91%
Pretax Income	$9.298M	$10.23M
YoY Change	-258.45%	-82.26%
Income Tax	$4.134M	$4.481M
% Of Pretax Income	44.46%	43.8%
Net Earnings	$5.164M	$5.750M
YoY Change	-154.65%	-86.95%
Net Earnings / Revenue	7.99%	8.67%
Basic Earnings Per Share	$0.39	$0.44
Diluted Earnings Per Share	$0.39	$0.44
COMMON SHARES
Basic Shares Outstanding	13.09M shares	13.08M shares
Diluted Shares Outstanding	13.15M shares	13.15M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$15.35M	$21.90M
YoY Change	-58.01%	-71.0%
Cash & Equivalents	$15.35M	$21.90M
Short-Term Investments
Other Short-Term Assets	$3.820M	$2.575M
YoY Change	-73.22%	-45.93%
Inventory	$42.48M	$44.14M
Prepaid Expenses
Receivables	$115.1M	$115.0M
Other Receivables	$1.144M	$1.069M
Total Short-Term Assets	$187.3M	$192.5M
YoY Change	-3.71%	-19.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.013M	$1.116M
YoY Change	-30.57%	-31.41%
Goodwill	$45.03M	$45.03M
YoY Change		13.31%
Intangibles	$107.4M	$112.9M
YoY Change		1035.56%
Long-Term Investments
YoY Change
Other Assets	$33.41M	$33.51M
YoY Change	10.21%	349.32%
Total Long-Term Assets	$217.6M	$221.7M
YoY Change	16.16%	177.11%
TOTAL ASSETS
Total Short-Term Assets	$187.3M	$192.5M
Total Long-Term Assets	$217.6M	$221.7M
Total Assets	$404.8M	$414.2M
YoY Change	6.04%	29.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$15.84M	$17.11M
YoY Change	-20.67%	17.91%
Accrued Expenses	$61.33M	$73.20M
YoY Change	7.83%	15.44%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$8.297M	$7.500M
YoY Change	-62.02%	-68.35%
Total Short-Term Liabilities	$86.63M	$97.81M
YoY Change	-20.5%	-3.77%
LONG-TERM LIABILITIES
Long-Term Debt	$61.90M	$68.83M
YoY Change	120.92%
Other Long-Term Liabilities	$4.256M	$4.692M
YoY Change	88.65%	83.07%
Total Long-Term Liabilities	$66.15M	$73.52M
YoY Change	118.51%	2768.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$86.63M	$97.81M
Total Long-Term Liabilities	$66.15M	$73.52M
Total Liabilities	$152.8M	$171.3M
YoY Change	6.27%	64.42%
SHAREHOLDERS EQUITY
Retained Earnings	$122.4M	$117.3M
YoY Change		-2.22%
Common Stock	$18.00K	$18.00K
YoY Change		5.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$252.0M	$242.8M
YoY Change
Total Liabilities & Shareholders Equity	$404.8M	$414.2M
YoY Change	6.04%	29.36%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	$5.164M	$5.750M
YoY Change	-154.65%	-86.95%
Depreciation, Depletion And Amortization	$100.0K	$100.0K
YoY Change	-93.88%	-50.0%
Cash From Operating Activities	-$126.0K	-$33.51M
YoY Change	-100.29%	101.75%
INVESTING ACTIVITIES
Capital Expenditures	$6.000K	$58.00K
YoY Change		-65.48%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$12.50M
YoY Change	-100.0%
Cash From Investing Activities	-$6.000K	-$12.56M
YoY Change	-99.99%	7375.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$1.250M
YoY Change		-37.5%
Cash From Financing Activities	-6.411M	$12.65M
YoY Change	1096.08%	-211.34%
NET CHANGE
Cash From Operating Activities	-126.0K	-$33.51M
Cash From Investing Activities	-6.000K	-$12.56M
Cash From Financing Activities	-6.411M	$12.65M
Net Change In Cash	-6.543M	-$33.42M
YoY Change	-80.15%	18.79%
FREE CASH FLOW
Cash From Operating Activities	-$126.0K	-$33.51M
Capital Expenditures	$6.000K	$58.00K
Free Cash Flow	-$132.0K	-$33.57M
YoY Change	-100.31%	100.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000827871
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-36306
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Eagle Pharmaceuticals, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8179278
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	50 Tice Boulevard
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 315
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Woodcliff Lake
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07677
CY2023Q1	dei	City Area Code CityAreaCode	(201)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	326-5300
CY2023Q1	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	EGRX
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13091344	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21897000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55321000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	114953000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	72439000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	44140000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	47794000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11501000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13200000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	192491000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	188754000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1116000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1168000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	112875000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	118327000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	45033000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	45033000	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	29150000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	27146000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33510000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	25732000	usd
CY2023Q1	us-gaap	Assets Assets	414175000	usd
CY2022Q4	us-gaap	Assets Assets	406160000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	17108000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18993000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	73201000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	85844000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	7500000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	6250000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	97809000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	111087000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	68829000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	56216000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4692000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5297000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	171330000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	172600000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17636973	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17569375	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	18000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	18000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	369800000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	366265000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1112000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1112000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	117254000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	111504000	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4552730	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4552730	shares
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	243115000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	243115000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	242845000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	233560000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	414175000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	406160000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	66305000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	115874000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	17300000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	25176000	usd
CY2023Q1	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2022Q1	us-gaap	Royalty Expense RoyaltyExpense	2579000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9272000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6108000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27960000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22182000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	54532000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	56045000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	11773000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	59829000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	212000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	154000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1516000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	366000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-238000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1957000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1542000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2169000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	10231000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	57660000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4481000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13602000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	5750000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	44058000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.44
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.47
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.44
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.41
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13059153	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12710646	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13153271	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12906811	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	5750000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	44058000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	512000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	512000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5750000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	44570000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	233560000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4639000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-1104000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	5750000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	242845000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	176453000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4295000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-1305000	usd
CY2022Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	8053000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	512000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	44058000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	44058000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	215960000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	5750000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	44058000	usd
CY2023Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-2183000	usd
CY2022Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-2432000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	110000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	177000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	333000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	290000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5450000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	731000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-403000	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-2530000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4639000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4295000	usd
CY2023Q1	egrx	Debt Securities Available For Sale Credit Loss Expense Reversal DebtSecuritiesAvailableForSaleCreditLossExpenseReversal	0	usd
CY2022Q1	egrx	Debt Securities Available For Sale Credit Loss Expense Reversal DebtSecuritiesAvailableForSaleCreditLossExpenseReversal	36000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	113000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	118000	usd
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	77000	usd
CY2022Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	608000	usd
CY2023Q1	egrx	Accretion Income AccretionIncome	0	usd
CY2022Q1	egrx	Accretion Income AccretionIncome	45000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	42515000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	89710000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3654000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2910000	usd
CY2023Q1	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-1700000	usd
CY2022Q1	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	1948000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1884000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1651000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-8633000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	30800000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	372000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	342000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33512000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16611000	usd
CY2023Q1	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	12500000	usd
CY2022Q1	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	0	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	58000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	168000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12558000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-168000	usd
CY2023Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	15000000	usd
CY2022Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1104000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1305000	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1250000	usd
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2000000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	8053000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12646000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11358000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-33424000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-28137000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55321000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97659000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21897000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69522000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	200000	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	41000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1316000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	265000	usd
CY2023Q1	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation and Other Company Information <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting quarterly information. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. The condensed consolidated balance sheet at December 31, 2022 was derived from audited financial statements, but certain information and footnote disclosures normally included in our annual consolidated financial statements have been condensed or omitted. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results for the year ending December 31, 2023 or any period thereafter. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 23, 2023. </span></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eagle Pharmaceuticals, Inc. (the "Company", "Eagle", or "we") is an integrated pharmaceutical company focused on finding ways to help medicines do more for patients. We and our collaborators have the capabilities to take a molecule from preclinical research through regulatory approval and into the marketplace, including development, manufacturing and commercialization. Our business model applies our scientific expertise, proprietary research-based insights and marketplace proficiency to identify challenging-to-treat diseases of the central nervous system or metabolic critical care therapeutic areas as well as in oncology. By focusing on patients' unmet needs, we strive to provide healthcare professionals with urgently needed treatment solutions that are designed to improve patient care and outcomes and create near- and long-term value for our stakeholders, including patients and healthcare providers and our employees, marketing partners, collaborators and investors. Our science-based business model has a proven track record with the U.S. Food and Drug Administration ("FDA") approval and commercial launches of six products: PEMFEXY® (pemetrexed for injection), vasopressin, an A-rated generic alternative to Vasostrict®, Ryanodex® (dantrolene sodium) ("Ryanodex"), bendamustine ready-to-dilute ("RTD") 500ml solution ("Belrapzo"), and rapidly infused bendamustine RTD ("Bendeka") and bendamustine ready-to-dilute and rapidly infused RTD in Japan (“Treakisym”). We market our products through marketing partners and/or our internal direct sales force. We market PEMFEXY, vasopressin, Ryanodex and Belrapzo, and Teva Pharmaceutical Industries Ltd. ("Teva") markets Bendeka through its subsidiary Cephalon, Inc. SymBio Pharmaceuticals Limited ("SymBio"), markets Treakisym, a RTD product, in Japan.</span></div>On June 9, 2022, we acquired all of the outstanding share capital of Acacia Pharma Group plc (“Acacia”), which added two FDA approved new chemical entities with patent protection, BARHEMSYS® (amisulpride for injection) and BYFAVO® (remimazolam for injection). Refer to Note 13 for further details.
CY2023Q1	egrx	Number Of Products Launched NumberOfProductsLaunched	6	product
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These condensed consolidated financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements including disclosure of gross to net estimates as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. Our critical accounting policies are those that are both most important to our financial condition and results of operations and also require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertai</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n. As of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, assumptions and judgments or revise the carrying value of our assets or liabilities. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the condensed consolidated financial statements, actual results may materially vary from these estimates, and any such differences may be material to our condensed consolidated financial statements.</span></div>
CY2023Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	17702000	usd
CY2023Q1	us-gaap	Other Assets Fair Value Disclosure OtherAssetsFairValueDisclosure	8125000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	47567000	usd
CY2022Q4	us-gaap	Other Assets Fair Value Disclosure OtherAssetsFairValueDisclosure	8125000	usd
CY2022Q4	us-gaap	Fair Value Liabilities Measured On Recurring Basis Obligations FairValueLiabilitiesMeasuredOnRecurringBasisObligations	4063000	usd
CY2022Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	3700000	usd
CY2022Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1700000	usd
CY2023Q1	egrx	Revenue From Contract With Customer Wholesaler Discount RevenueFromContractWithCustomerWholesalerDiscount	0.02
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2548719	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2183268	shares
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	5750000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5750000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	44058000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	44058000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13059153	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12710646	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	94118	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	196165	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13153271	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12906811	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.44
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.47
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.44
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.41
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7827000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7769000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6711000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6601000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1116000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1168000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	12198000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	12348000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	9386000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	14064000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	22556000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	21382000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	44140000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	47794000	usd
CY2023Q1	us-gaap	Prepaid Taxes PrepaidTaxes	306000	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	90000	usd
CY2023Q1	egrx	Prepaid Fda User Fee And Advances To Clinical Research Organizations PrepaidFDAUserFeeAndAdvancesToClinicalResearchOrganizations	1506000	usd
CY2022Q4	egrx	Prepaid Fda User Fee And Advances To Clinical Research Organizations PrepaidFDAUserFeeAndAdvancesToClinicalResearchOrganizations	3022000	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	1661000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	258000	usd
CY2023Q1	egrx	Advances To Commercial Manufacturers AdvancesToCommercialManufacturers	3630000	usd
CY2022Q4	egrx	Advances To Commercial Manufacturers AdvancesToCommercialManufacturers	5464000	usd
CY2023Q1	egrx	Prepaid Research And Development PrepaidResearchAndDevelopment	754000	usd
CY2022Q4	egrx	Prepaid Research And Development PrepaidResearchAndDevelopment	106000	usd
CY2023Q1	egrx	Pass Through Receivables PassThroughReceivables	1069000	usd
CY2022Q4	egrx	Pass Through Receivables PassThroughReceivables	1001000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	2575000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3259000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11501000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13200000	usd
CY2023Q1	egrx	Accrued Product Sales Reserves Current AccruedProductSalesReservesCurrent	38327000	usd
CY2022Q4	egrx	Accrued Product Sales Reserves Current AccruedProductSalesReservesCurrent	33000000	usd
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	12583000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	5182000	usd
CY2023Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	6306000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7205000	usd
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3856000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5293000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5688000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5541000	usd
CY2023Q1	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	628000	usd
CY2022Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1549000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1587000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1534000	usd
CY2023Q1	egrx	Inventory Received But Not Invoiced InventoryReceivedButNotInvoiced	3319000	usd
CY2022Q4	egrx	Inventory Received But Not Invoiced InventoryReceivedButNotInvoiced	6779000	usd
CY2023Q1	us-gaap	Nonfinancial Liabilities Fair Value Disclosure NonfinancialLiabilitiesFairValueDisclosure	0	usd
CY2022Q4	us-gaap	Nonfinancial Liabilities Fair Value Disclosure NonfinancialLiabilitiesFairValueDisclosure	4063000	usd
CY2023Q1	egrx	Royalty Buy Down Payable RoyaltyBuyDownPayable	0	usd
CY2022Q4	egrx	Royalty Buy Down Payable RoyaltyBuyDownPayable	15000000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	907000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	698000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	73201000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	85844000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P1Y10M24D
CY2023Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	421000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1507000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	421000	usd
CY2022	us-gaap	Lease Cost LeaseCost	1507000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	421000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1507000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1587000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1055000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2642000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	134783000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	21908000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	112875000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	134783000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	16456000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	118327000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5500000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	700000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	16483000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	19780000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	13917000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	11615000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	11615000	usd
CY2023Q1	egrx	Finite Lived Intangible Assets Expected Amortization After Year Four FiniteLivedIntangibleAssetsExpectedAmortizationAfterYearFour	39465000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	112875000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2814878	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	86700	shares
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	3130	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2898448	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2425833	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	111268	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	6696	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2530405	shares
CY2023Q1	egrx	Number Of Share Of Common Stock Holder Has A Right To NumberOfShareOfCommonStockHolderHasARightTo	1	commonstock
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4639000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4295000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4639000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4295000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2792000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1257000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1122000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	413000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	0	usd
CY2023Q1	egrx	Lessee Operating Lease Liability To Be Paid After Year Three LesseeOperatingLeaseLiabilityToBePaidAfterYearThree	0	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	77500000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	5000000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	10000000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	62500000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2023Q1	egrx	Long Term Debt Maturity After Year Three LongTermDebtMaturityAfterYearThree	0	usd
CY2023Q1	us-gaap	Purchase Obligation PurchaseObligation	86491000	usd
CY2023Q1	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	86491000	usd
CY2023Q1	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	0	usd
CY2023Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	0	usd
CY2023Q1	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	usd
CY2023Q1	egrx	Purchase Obligation To Be Paid After Year Three PurchaseObligationToBePaidAfterYearThree	0	usd
CY2023Q1	egrx	Obligation Obligation	166783000	usd
CY2023Q1	egrx	Obligation To Be Paid Remainder Of Fiscal Year ObligationToBePaidRemainderOfFiscalYear	92748000	usd
CY2023Q1	egrx	Obligation To Be Paid Year One ObligationToBePaidYearOne	11122000	usd
CY2023Q1	egrx	Obligation To Be Paid Year Two ObligationToBePaidYearTwo	62913000	usd
CY2023Q1	egrx	Obligation To Be Paid Year Three ObligationToBePaidYearThree	0	usd
CY2023Q1	egrx	Obligation To Be Paid After Year Three ObligationToBePaidAfterYearThree	0	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	400000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	400000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2800000	usd
CY2023Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	7500000	usd
CY2023Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1200000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	5000000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	10000000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	62500000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	77500000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4481000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13602000	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.44
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.24
CY2023Q1	egrx	Number Of Tax Jurisdictions Currently Auditing The Company NumberOfTaxJurisdictionsCurrentlyAuditingTheCompany	3	jurisdiction
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q1	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	12500000	usd

Files In Submission

Name	View Source	Status
egrx-20230331_pre.xml	Edgar Link	unprocessable
0000827871-23-000016-index-headers.html	Edgar Link	pending
0000827871-23-000016-index.html	Edgar Link	pending
0000827871-23-000016.txt	Edgar Link	pending
0000827871-23-000016-xbrl.zip	Edgar Link	pending
egrx-20230331.htm	Edgar Link	pending
egrx-20230331.xsd	Edgar Link	pending
egrx-20230331_def.xml	Edgar Link	unprocessable
egrx-20230331_cal.xml	Edgar Link	unprocessable
egrx-20230331_lab.xml	Edgar Link	unprocessable
egrx-20230331_htm.xml	Edgar Link	completed
exhibit311q12023.htm	Edgar Link	pending
exhibit312q12023.htm	Edgar Link	pending
exhibit321q12023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

2023 Q2 Form 10-Q Financial Statement

#000082787123000016 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX EAGLE PHARMACEUTICALS, INC. Stock $egrx

2023 Q2 Form 10-Q Financial Statement

#000082787123000016 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx